Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPAX 1050TG
- Development stage
- Unknown
- Lead developer
- Epax
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EPAX 1050TG is a concentrated omega-3 fatty acid preparation in triglyceride form, specifically formulated with a high ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA). Developed by Epax Norway AS, it contains approximately 50% DHA and 10% EPA. The product was notably used in the OmegAD clinical trial (NCT00211159) sponsored by Karolinska University Hospital to investigate whether high-dose DHA supplementation could slow cognitive decline in patients with mild to moderate Alzheimer's disease. DHA is a primary structural component of the brain and is thought to support neuronal function, reduce neuroinflammation, and potentially interfere with the formation of amyloid plaques.
- Brand names
- EPAX 1050TGEPAX1050TGEPAX-1050TG
- Other names
- Omega-3 fatty acid concentrateOmega3 fatty acid concentrateOmega 3 fatty acid concentrateDHA-rich omega-3 concentrate
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on EPAX 1050TG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPAX 1050TG.